Literature DB >> 33944948

Customizing CAT Administration of the PROMIS Misuse of Prescription Pain Medication Item Bank for Patients with Chronic Pain.

Dokyoung S You1, Karon F Cook2, Benjamin W Domingue3, Maisa S Ziadni1, Jennifer M Hah1, Beth D Darnall1, Sean C Mackey1.   

Abstract

OBJECTIVE: The 22-item PROMIS®-Rx Pain Medication Misuse item bank (Bank-22) imposes a high response burden. This study aimed to characterize the performance of the Bank-22 in a computer adaptive testing (CAT) setting based on varied stopping rules.
METHODS: The 22 items were administered to 288 patients. We performed a CAT simulation using default stopping rules (CATPROMIS). In 5 other simulations, a "best health" response rule was added to decrease response burden. This rule stopped CAT administration when a participant selected "never" to a specified number of initial Bank-22 items (2-6 in this study, designated CATAlt2-Alt6). The Bank-22 and 7-item short form (SF-7) scores were compared to scores based on CATPROMIS, and the 5 CAT variations.
RESULTS: Bank-22 scores correlated highly with the SF-7 and CATPROMIS, Alt5, Alt6 scores (r=0.87-0.95) and moderately with CATAlt2- Alt4 scores (r=0.63-0.74). In all CAT conditions, the greatest differences with Bank-22 scores were at the lower end of misuse T-scores. The smallest differences with Bank-22 and CATPROMIS scores were observed with CATAlt5 and CATAlt6. Compared to the SF-7, CATAlt5 and CATAlt6 reduced overall response burden by about 42%. Finally, the correlations between PROMIS-Rx Misuse and Anxiety T-scores remained relatively unchanged across the conditions (r=0.31-0.43, Ps < .001).
CONCLUSIONS: Applying a stopping rule based on number of initial "best health" responses reduced response burden for respondents with lower levels of misuse. The tradeoff was less measurement precision for those individuals, which could be an acceptable tradeoff when the chief concern is in discriminating higher levels of misuse.
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Academy of Pain Medicine.All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Computer Adaptive Testing; NIH PROMIS; Opioid Misuse; PROMIS-Rx Pain Medication Misuse; Prescription Opioids

Mesh:

Year:  2021        PMID: 33944948      PMCID: PMC8488966          DOI: 10.1093/pm/pnab159

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  14 in total

1.  Grooming a CAT: customizing CAT administration rules to increase response efficiency in specific research and clinical settings.

Authors:  Michael A Kallen; Karon F Cook; Dagmar Amtmann; Elizabeth Knowlton; Richard C Gershon
Journal:  Qual Life Res       Date:  2018-05-05       Impact factor: 4.147

2.  Reducing survey burden: feasibility and validity of PROMIS measures in multiple sclerosis.

Authors:  Angela Senders; Douglas Hanes; Dennis Bourdette; Ruth Whitham; Lynne Shinto
Journal:  Mult Scler       Date:  2014-01-08       Impact factor: 6.312

3.  The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008.

Authors:  David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays
Journal:  J Clin Epidemiol       Date:  2010-08-04       Impact factor: 6.437

4.  Evaluation of the Preliminary Validity of Misuse of Prescription Pain Medication Items from the Patient-Reported Outcomes Measurement Information System (PROMIS)®.

Authors:  Dokyoung Sophia You; Jennifer M Hah; Sophie Collins; Maisa S Ziadni; Ben W Domingue; Karon F Cook; Sean C Mackey
Journal:  Pain Med       Date:  2019-10-01       Impact factor: 3.750

Review 5.  Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations.

Authors:  Shannon M Smith; Richard C Dart; Nathaniel P Katz; Florence Paillard; Edgar H Adams; Sandra D Comer; Aldemar Degroot; Robert R Edwards; David J Haddox; Jerome H Jaffe; Christopher M Jones; Herbert D Kleber; Ernest A Kopecky; John D Markman; Ivan D Montoya; Charles O'Brien; Carl L Roland; Marsha Stanton; Eric C Strain; Gary Vorsanger; Ajay D Wasan; Roger D Weiss; Dennis C Turk; Robert H Dworkin
Journal:  Pain       Date:  2013-06-20       Impact factor: 6.961

6.  Minimal Clinically Important Difference After Carpal Tunnel Release Using the PROMIS Platform.

Authors:  Nikolas H Kazmers; Man Hung; Jerry Bounsanga; Maren W Voss; Abby Howenstein; Andrew R Tyser
Journal:  J Hand Surg Am       Date:  2019-05-06       Impact factor: 2.230

7.  Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy.

Authors:  Stephen F Butler; Simon H Budman; Gilbert J Fanciullo; Robert N Jamison
Journal:  Clin J Pain       Date:  2010 Nov-Dec       Impact factor: 3.442

8.  Clinical validity of PROMIS Depression, Anxiety, and Anger across diverse clinical samples.

Authors:  Benjamin D Schalet; Paul A Pilkonis; Lan Yu; Nathan Dodds; Kelly L Johnston; Susan Yount; William Riley; David Cella
Journal:  J Clin Epidemiol       Date:  2016-02-27       Impact factor: 6.437

9.  Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients.

Authors:  Laura L Adams; Robert J Gatchel; Richard C Robinson; Peter Polatin; Noor Gajraj; Martin Deschner; Carl Noe
Journal:  J Pain Symptom Manage       Date:  2004-05       Impact factor: 3.612

10.  Prescription Opioid Misuse Index: a brief questionnaire to assess misuse.

Authors:  Janet S Knisely; Martha J Wunsch; Karen L Cropsey; Eleanor D Campbell
Journal:  J Subst Abuse Treat       Date:  2008-07-26
View more
  1 in total

1.  Calibration of the Dutch EyeQ to Measure Vision Related Quality of Life in Patients With Exudative Retinal Diseases.

Authors:  T Petra Rausch-Koster; Michiel A J Luijten; F D Verbraak; Ger H M B van Rens; Ruth M A van Nispen
Journal:  Transl Vis Sci Technol       Date:  2022-04-01       Impact factor: 3.283

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.